Pharmaceuticals Signs Agreement with Mixture Sciences, Inc. Mixture
to provide diverse collection of peptide and peptide-derived small molecule
compounds to support the discovery of new antibacterial agents.
San Diego, CA - November 20, 2003 - Mpex Pharmaceuticals,
Inc. ("Mpex") and Mixture Sciences, Inc. ("Mixture")
announced today that they have entered into a research collaboration that
utilizes Mixture's combinatorial libraries to identify novel lead compounds
appropriate for antibacterial development by Mpex.
Mpex is pursuing the discovery of new broad-spectrum antibiotics that
meet the growing clinical need created by multi-drug resistant bacterial
pathogens. To identify these new agents, Mpex is utilizing its proprietary
assay technology to screen new sources of diversity to identify agents
that have activity against the Mpex targets. "Mixture has one of
the most extensive libraries of peptide and peptide-derived small molecule
compounds," states Bill Gerhart, President and CEO of Mpex. "We
believe this unique source of diversity will result in promising lead
compounds against one or more of the Mpex targets."
Mixture Sciences, Inc., www.mixturesciences.com,
is a privately held biotechnology company specializing in biomedical research
and drug discovery. Mixture uses a combination of proprietary and in-licensed
technologies for the discovery of therapeutic and diagnostic candidates
for the treatment of HIV/AIDS, cancer, diabetes, multiple sclerosis, and
infectious diseases, including Lyme Disease. The Mixture technologies
have been validated and used by numerous members of the academic and corporate
community over the past decade. "Our success comes from being a worldwide
leader in the use of mixture-based chemical libraries," states Richard
Houghten, President and CEO of Mixture. "Our unique position allows
us to provide our collaborators exceptional technologies and expertise."
Mixture Sciences, Inc. is committed to developing, improving, patenting
and in-licensing new technologies in order to provide our collaborators
with the most cost efficient methods for identifying ligands.
Mpex Pharmaceuticals, Inc., www.mpexpharma.com,
is an early-stage, privately held biotechnology company founded in 2001
to apply its proprietary membrane protein expression ("Mpex")
technology to the discovery of new antibacterials. Mpex is uniquely targeting
channels, transporters, and other novel membrane protein targets to develop
new broad-spectrum antibiotics with stronger Gram-negative activity. The
Company is utilizing its proprietary technologies, extensive antimicrobial
expertise, and collaborative relationships to identify and validate these
novel targets and has thus far initiated two research programs focused
on novel compounds that potentiate antibiotics to significantly increase
their spectrum of activity.